Rudolph Marc D, Sutphen Courtney L, Register Thomas C, Lockhart Samuel N, Rundle Melissa M, Hughes Timothy M, Bateman James R, Sai Kiran K Solingapuram, Whitlow Christopher T, Craft Suzanne, Mielke Michelle M
Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Alzheimers Dement. 2025 Jul;21(7):e70426. doi: 10.1002/alz.70426.
Studies suggest excellent performance of plasma phosphorylated tau 217 (p-tau217) for detecting amyloid pathology, though studies in more representative populations are needed to validate previously determined cutpoints.
Plasma p-tau217 utility for detecting amyloid pathology (Aβ) via amyloid positron emission tomography (PET) was assessed in a heterogeneous, community-based cohort in the Wake Forest Alzheimer's Disease Research Center (WFADRC). Participants with baseline plasma data (n = 598) were 21% Black; 313 cognitive unimpaired (CU), 214 mild cognitive impairment (MCI), and 64 dementia (DEM); 49% prediabetic, 44% hypertensive, 29% overweight/obese; and 64% had mild-to-moderate kidney disease. Gaussian-mixture models, logistic regression, and receiver operating curve analyses were performed.
Plasma p-tau217 was associated with elevated Aβ deposition and accurately classified Aβ-positive participants (PET [n = 307]: area under the curve [AUC] = 94%-97%, cutpoint ≥ 0.338 pg/mL).
Plasma p-tau217 is an accurate indicator of amyloid pathology in a heterogeneous cohort and is superior to other plasma biomarkers assessed.
The Wake Forest Alzheimer's Disease Research Center (WFADRC) is a heterogeneous cohort. p-tau217 levels were lower, on average, in cognitively unimpaired participants, females, and Black participants. Plasma p-tau217 classified amyloid positron emission tomography (PET)-positive individuals with high precision and performed better than p-tau181. Cutpoints and reference ranges of plasma p-tau217 were lower compared to recently published thresholds. Combining cutpoint approaches, a four-tier system captured cohort heterogeneity.
研究表明血浆磷酸化tau 217（p-tau217）在检测淀粉样蛋白病变方面表现出色，不过需要在更具代表性的人群中进行研究，以验证先前确定的切点。
在维克森林大学阿尔茨海默病研究中心（WFADRC）的一个基于社区的异质性队列中，评估了血浆p-tau217通过淀粉样蛋白正电子发射断层扫描（PET）检测淀粉样蛋白病变（Aβ）的效用。有基线血浆数据的参与者（n = 598）中，21%为黑人；313名认知未受损（CU），214名轻度认知障碍（MCI），64名痴呆（DEM）；49%患有糖尿病前期，44%患有高血压，29%超重/肥胖；64%患有轻度至中度肾病。进行了高斯混合模型、逻辑回归和受试者工作特征曲线分析。
血浆p-tau217与Aβ沉积增加相关，并能准确分类Aβ阳性参与者（PET[n = 307]：曲线下面积[AUC]=94%-97%，切点≥0.338 pg/mL）。
血浆p-tau217是异质性队列中淀粉样蛋白病变的准确指标，优于所评估的其他血浆生物标志物。
维克森林大学阿尔茨海默病研究中心（WFADRC）是一个异质性队列。认知未受损参与者、女性和黑人参与者的p-tau217水平平均较低。血浆p-tau217对淀粉样蛋白正电子发射断层扫描（PET）阳性个体的分类精度很高，且表现优于p-tau181。与最近公布的阈值相比，血浆p-tau217的切点和参考范围更低。结合切点方法，一个四层系统捕捉了队列的异质性。
